Biologic drugs have revolutionized healthcare for various hard-to-treat conditions, yet access remains restricted, especially in emerging markets, largely owing to the high cost of these drugs.
Read more
Interferon and erythropoietin therapies are essential for treating a range of conditions including viral infections, kidney diseases, neurological disorders, and cancer.
Read more
Ensuring the safety, quality, and efficacy of biosimilars is essential to garnering confidence in these cost-saving medicines by both physicians and patients.
Read more
Biologic drugs have revolutionized the treatment landscape for many severe and chronic conditions, providing targeted therapies for diseases like rheumatoid arthritis, various forms of cancer, diabetes, and multiple sclerosis.
Read more
Today, more than 70% of the global population suffer from chronic diseases, many of which require expensive biologic medications.
Read more
The company that is pioneer in biotechnology and is committed to its three-fold value creation, social, environmental and economic, certified its plants in Bernal and Almagro and its logistics center in Quilmes under the ISO 14001 and ISO 45001 norms.
Read more
The company Biosidus, leader in biotechnology, presents its first sustainability report, in accordance with their commitment to the society and given the operative characteristics of their work and the challenge that healthcare represents.
Read more
Pablo Salvagni, who took the role of regional manager for Latam in the years 2015 and 2016, was appointed commercial director for North Latam.
Read more